AI Article Synopsis

  • Integrin α4β7 is crucial for lymphocyte movement to the gut, impacting conditions like inflammatory bowel disease (IBD).
  • Loss of β7 integrin function in mouse models led to worsened colitis by impairing Treg cell homing to the gut, although their suppressive abilities remained intact.
  • These findings indicate that IBD patients with diminished Treg activity or interleukin 10 may not respond well to therapies targeting α4β7.

Article Abstract

Background & Aims: Integrin α4β7 mediates lymphocyte trafficking to the gut and gut-associated lymphoid tissues, a process critical for recruitment of effector lymphocytes from the circulation to the gut mucosa in inflammatory bowel disease (IBD) and murine models of intestinal inflammation. Antibody blockade of β7 integrins generally is efficacious in IBD; however, some patients fail to respond, and a few patients can experience exacerbations. This study examined the effects of loss of β7 integrin function in murine models of IBD.

Methods: In a mouse IBD model caused by lack of interleukin 10, a cytokine important in CD25FoxP3 regulatory T cell (Treg) function, genetic deletion of β7 integrin or antibody blockade of α4β7-mucosal addressin cell adhesion molecule-1 interaction paradoxically exacerbated colitis.

Results: Loss of β7 impaired the capacity of Tregs homing to the gut and therefore suppress intestinal inflammation in an adoptive T-cell transfer model; however, the intrinsic suppressive function of β7-deficient Tregs remained intact, indicating that the β7 deficiency selectively impacts gut homing. Deletion of β7 integrin did not worsen colitis in an acute dextran sodium sulfate model in which Treg number and function were normal.

Conclusions: In Integrin subunit beta (Itgb)7Il10 mice, loss of β7-dependent Treg homing to gut-associated lymphoid tissues combined with loss of intrinsic Treg function exacerbated intestinal inflammation. These results suggest that IBD patients with reduced CD25FoxP3 Treg numbers or function or lack of interleukin 10 could be at risk for failure of α4β7 blocking therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016000PMC
http://dx.doi.org/10.1016/j.jcmgh.2019.10.012DOI Listing

Publication Analysis

Top Keywords

β7 integrin
16
intestinal inflammation
16
cd25foxp3 regulatory
8
gut-associated lymphoid
8
lymphoid tissues
8
murine models
8
antibody blockade
8
ibd patients
8
loss β7
8
lack interleukin
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!